2616 — CStone Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- HK$2.09bn
- HK$1.57bn
- CNY463.84m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 1,039 | 244 | 481 | 464 |
Cost of Revenue | |||||
Gross Profit | — | 797 | 137 | 278 | 304 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,308 | 2,259 | 2,162 | 1,376 | 819 |
Operating Profit | -2,308 | -1,220 | -1,918 | -894 | -355 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2,308 | -1,221 | -1,920 | -903 | -367 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2,308 | -1,221 | -1,920 | -903 | -367 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -2,308 | -1,221 | -1,920 | -903 | -367 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2,069 | -1,221 | -1,920 | -903 | -367 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.37 | -1.17 | -1.65 | -0.75 | -0.411 |